La cadena de opciones muestra datos clave de las opciones de acciones de Intellia Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Intellia Therapeutics..

Intellia Therapeutics (NASDAQ:NTLA) Bolsa, Cadena de Opciones

INTELLIA THERAPEUTICS INC

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

News

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

ILMN

NTLA

OKLO

PATH

Descubre las recientes decisiones de Ark Invest en energía, defensa y genética, con transacciones millonarias en empresas clave.

Ark Invest adquiere y vende acciones clave en energía, defensa y tecnología genética

Earnings

Earnings Beats

NMIH

CORRECTION: NMI Holdings Q2 Adj. EPS $1.22, Inline, Sales $173.779M Beat $147.955M Estimate

Seagate Technology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) reported fourth-quarter financial results for fiscal 2025 after the market close on Tuesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/07/b46704764/seagate-technology-reports-fiscal-fourth-quarter-and-fiscal-year-2025-financial-results">of the report</a>.
<ul class="wp-block-list">
<li>Q4 Revenue: $2.44 billion, versus <a href="http://benzinga.com/quote/STX/earnings">estimates</a> of $2.42 billion</li>
</ul>
<ul class="wp-block-list">
<li>Q4 Adjusted EPS: $2.59, versus estimates of $2.43</li>
</ul>
STX shares are currently under heavy selling pressure. <a href="https://www.benzinga.com/quote/STX" target="_blank" rel="noreferrer noopener">See the chart here.</a>
Seagate said it generated $508 million in cash flow from operations and $425 million in free cash flow in the quarter. The company had $891 million in total cash and cash equivalents at the end of the quarter. 
&#8220;Seagate&#8217;s strong FQ4 performance underscores our commitment to profitable growth, marked by a&nbsp;30%&nbsp;year-over-year revenue increase, record gross margin, and non-GAAP EPS expanding to the top of our&nbsp;guidance&nbsp;range,&#8221; said Dave Mosley, CEO of Seagate.
&#8220;These achievements reflect the structural enhancements we&#8217;ve implemented in our business and ongoing demand strength from cloud customers for our high-capacity drives.&#8221;
Seagate&#8217;s board declared a quarterly cash dividend of 72 cents per share, payable on Oct. 9 to shareholders of record as of Sept. 30. The company paid $153 million of cash dividends in the second quarter.
Guidance: Seagate expects fiscal first-quarter revenue to be in the range of $2.35 billion to $2.65 billion versus estimates of $2.5 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company sees first-quarter adjusted earnings of $2.10 to $2.50 per share versus estimates of $2.28 per share.
STX Price Action: <a href="http://benzinga.com/quote/STX">Seagate shares</a> were down 7.64% in after-hours, trading at $141.02 at the time of publication on Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46706017/starbucks-q3-earnings-revenue-beat-eps-miss-turnaround-efforts-ahead-of-schedule">Starbucks Q3 Earnings: Revenue Beat, EPS Miss, Turnaround Efforts &#8216;Ahead Of Schedule&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46706276/electronic-arts-q1-earnings-highlights-revenue-beat-ceo-says-most-exciting-launch-slate-coming">Electronic Arts Q1 Earnings Highlights: Revenue Beat, CEO Says &#8216;Most Exciting Launch Slate&#8217; Coming</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Andrei+Stanescu">Sundry Photography</a>/Shutterstock.com

Guidance

Movers

Tech

Seagate Technology Beats Q4 Estimates On Continued Demand Strength From Cloud Customers

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 5 years by 13.91% on an annualized basis producing an average annual return of 27.99%. Currently, Fair Isaac has a market capitalization of $36.64 billion. 
Buying $100 In FICO: If an investor had bought $100 of FICO stock 5 years ago, it would be worth $342.69 today based on a price of $1505.06 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753823714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FICO

Here's How Much $100 Invested In Fair Isaac 5 Years Ago Would Be Worth Today

Republic Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) lowers FY2025 GAAP EPS guidance from $6.79-$6.87 to $6.72-$6.74 vs $6.86 analyst estimate. Affirms FY2025 sales outlook from $16.675 billion-$16.750 billion to $16.675 billion-$16.750 billion vs $16.872 billion estimate.

Republic Services Lowers FY2025 GAAP EPS Guidance from $6.79-$6.87 to $6.72-$6.74 vs $6.86 Est; Affirms FY2025 Sales Guidance of $16.675B-$16.750B vs $16.872B Est

ILPT

CORRECTION: Industrial Logistics Q2 FFO $0.21 Beats $0.20 Estimate, Sales $112.097M Beat $111.675M Estimate

Jones Trading analyst Jason Weaver maintains Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) with a Buy and lowers the price target from $15 to $12.5.

Price Target

Analyst Ratings

SEVN

Jones Trading Maintains Buy on Seven Hills Realty Trust, Lowers Price Target to $12.5

Tetra Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTI#NYSE">TTI</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.07 by 30.43 percent. This is a 28.57 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $173.87 million which beat the analyst consensus estimate of $172.46 million by 0.82 percent. This is a 1.13 percent increase over sales of $171.94 million the same period last year.

Tetra Technologies Q2 Adj. EPS $0.09 Beats $0.07 Estimate, Sales $173.87M Beat $172.46M Estimate

EcoSynthetix (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ECO#TSX">ECO</a>) reported quarterly sales of $5.005 million which missed the analyst consensus estimate of $51.880 million by 90.35 percent. This is a 57.19 percent increase over sales of $3.184 million the same period last year.

Earnings Misses

TSX:ECO

EcoSynthetix Q2 Sales $5.005M Miss $51.880M Estimate

FNWD

Finward Bancorp Q3 EPS $0.50 Beats $0.24 Estimate, Sales $16.628M Miss $16.850M Estimate

First National Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FN#TSX">FN</a>) reported quarterly earnings of $1.04 per share which missed the analyst consensus estimate of $1.50 by 30.67 percent. This is a 18.18 percent increase over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $621.300 million which beat the analyst consensus estimate of $495.991 million by 25.26 percent. This is a 15.39 percent increase over sales of $538.450 million the same period last year.

TSX:FN

First National Financial Q2 EPS $1.04 Misses $1.50 Estimate, Sales $621.300M Beat $495.991M Estimate

Power solutions company Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) reported better-than-expected financial results <a href="https://www.benzinga.com/earnings">after market close Tuesday</a>, sending shares higher.
What Happened: Qorvo reported first-quarter revenue of $818.8 million, beating a Street consensus estimate of $775.6 million, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729">from Benzinga Pro.</a>
The company reported earnings per share of 92 cents for the quarter, beating a Street consensus estimate of 63 cents per share.
"The Qorvo team delivered a strong fiscal 2026 first quarter," Qorvo CEO Bob Bruggeworth said.
The CEO said the company is working on a "broad set of initiatives" to enhance profitability and is already seeing early positive results.
Chief Financial Officer Grant Brown said the first-quarter results exceeded company guidance, including for earnings per share and gross margins.
"These improvements demonstrate the actions being undertaken across our product portfolio, business segments, and manufacturing footprint that will enable us to improve profitability as we advance through fiscal 2026 and into fiscal 2027," Brown said.
What's Next: The company is guiding for second quarter revenue in a range of $975 million to $1.075 billion, versus a Street estimate of $953.25 million according to Benzinga Pro.
The company&#8217;s guidance for non-GAAP earnings per share is $1.75 to $2.25 in the second quarter, compared to a Street estimate of $1.63.
"In the September quarter, we expect sequential growth and margin expansion to be supported by increases in Qorvo content and unit volumes in large customer programs."
QRVO Price Action: Qorvo stock is up 8.13% to $91.55 in after-hours trading Tuesday, versus a 52-week trading range of $49.46 to $123.41.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/04/45086001/qorvo-stock-rallies-after-solid-q4-results-strong-q1-guidance">Qorvo Stock Rallies After Solid Q4 Results, Strong Q1 Guidance</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

QRVO

Why Qorvo Stock Is Soaring After-Hours Tuesday

CTO Realty Growth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTO#NYSE">CTO</a>) affirms FY2025 FFO guidance from $1.93-$1.98 to $1.93-$1.98 vs $1.84 analyst estimate..

CTO Realty Growth Affirms FY2025 FFO Guidance of $1.93-$1.98 vs $1.84 Est

DBVT

DBV Technologies Q2 EPS $(0.31)

WIIM

PRPL

PRPL stock has given up its prior gain. Purple Innovation shares were trading higher after the company reported better-than-expected Q2 sales results.

Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) raises FY2026 GAAP EPS guidance from $2.91-$3.29 to $3.24-$3.55 vs $3.27 analyst estimate. Affirms FY2026 sales outlook from $3.200 billion-$3.450 billion to $3.200 billion-$3.450 billion vs $3.325 billion estimate.

Nextracker Raises FY2026 GAAP EPS Guidance from $2.91-$3.29 to $3.24-$3.55 vs $3.27 Est; Affirms FY2026 Sales Guidance of $3.200B-$3.450B vs $3.325B Est

Boardwalk REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BEI#TSX">BEI</a>) reported quarterly earnings of $1.00 per share. This is a 13.64 percent increase over earnings of $0.88 per share from the same period last year. The company reported $157.300 million in sales this quarter. This is a 5.50 percent increase over sales of $149.100 million the same period last year.

TSX:BEI

Boardwalk REIT Q2 FFO $1.00 Up From $0.88 YoY, Sales $157.300M Up From $149.100M YoY

Morguard North American (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRG#TSX">MRG</a>) reported quarterly earnings of $0.47 per share. This is a 14.63 percent increase over earnings of $0.41 per share from the same period last year. The company reported $88.537 million in sales this quarter. This is a 3.24 percent increase over sales of $85.756 million the same period last year.

TSX:MRG

Morguard North American Q2 FFO $0.47 Up From $0.41 YoY, Sales $88.537M Up From $85.756M YoY

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q3 Adj EPS of $0.69-$0.87 vs $0.89 analyst estimate. sees sales of $710.000 million-$770.000 million vs $757.606 million analyst estimate.

Teradyne Sees Q3 Adj EPS $0.69-$0.87 vs $0.89 Est; Sees Sales $710.000M-$770.000M vs $757.606M Est

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q3 GAAP EPS of $0.62-$0.80 vs $0.87 analyst estimate..

Teradyne Sees Q3 GAAP EPS $0.62-$0.80 vs $0.87 Est

<h3>Gainers</h3>
<ul>
<li>Rocky Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) stock rose 24.0% to $28.5 during Tuesday's after-market session. The market value of their outstanding shares is at $175.3 million. The company's, Q2 earnings came out today. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) shares moved upwards by 10.57% to $0.94. The company's market cap stands at $108.2 million. As per the news, the Q2 earnings report came out today. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock moved upwards by 9.59% to $0.05. The company's market cap stands at $5.9 million. </li>
<li>Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) shares rose 6.06% to $66.96. The market value of their outstanding shares is at $3.4 billion. The company's, Q2 earnings came out today. </li>
<li>Pitanium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTNM#NASDAQ">PTNM</a>) shares moved upwards by 6.03% to $1.4. The market value of their outstanding shares is at $40.5 million. </li>
<li>GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) stock rose 4.9% to $1.07. The company's market cap stands at $64.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 9.8% to $0.46 during Tuesday's after-market session. The market value of their outstanding shares is at $18.2 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares decreased by 8.28% to $1.22. The market value of their outstanding shares is at $318.4 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares declined by 4.93% to $0.19. The company's market cap stands at $9.5 million. </li>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares decreased by 4.43% to $2.05. The company's market cap stands at $8.2 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) shares fell 3.81% to $2.4. The market value of their outstanding shares is at $10.6 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock fell 3.78% to $1.02. The market value of their outstanding shares is at $85.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAKE

ECDA

GDHG

GRWG

NWTN

PTNM

RCKY

UCAR

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

Legal

Press Releases

Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLA

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Health Care

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

General

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Comments

Intellia Therapeutics

Intellia Therapeutics (NTLA) Opciones

Intellia Therapeutics (NASDAQ:NTLA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL